Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02315872 · ClinicalTrials.gov registry record · Phase 3
ACTH for Fatigue in Multiple Sclerosis Patients
A Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
- 5
- Study locations
NCT02315872: Completed Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Providence Health & Services.
NCT02315872 is a Phase 3 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Providence Health & Services. The registered enrollment target is 8 participants, below the 562-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02315872, a Phase 3 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.
Primary Outcome
Patient-reported levels of fatigue as measured by score on the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS) at 28 weeks. The full-length MFIS consists of 21 items. A higher score on the MFIS indicates a greater impact of fatigue on a patient's activities. The FSS is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. Higher scores on each scale indicate a greater severity
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ACTH
Study Locations (5)
Oregon
- Providence Medical Group - Medford Neurology - Medford
- Providence St. Vincent Medical Center - Portland
Washington
- Swedish Medical Center - Seattle
- MultiCare Health System -- Institute for Research and Innovation - Tacoma
Alabama
- North Central Neurology Associates, PC - Cullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05-22 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 3 |
What the finished NCT02315872 record still lists
NCT02315872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 562-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02315872 lists 5 locations in 3 states (Oregon, Washington, Alabama).
Frequently Asked Questions
What is clinical trial NCT02315872 about?
NCT02315872 is a clinical study titled "ACTH for Fatigue in Multiple Sclerosis Patients". This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.
What is the current status of trial NCT02315872?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2015-05-22. Estimated completion is 2018-12-13.
What conditions does trial NCT02315872 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT02315872?
The interventions under investigation include: Placebo (DRUG), ACTH (DRUG).
Who is sponsoring clinical trial NCT02315872?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02315872 being conducted?
This trial has 5 study locations across Alabama, Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02315872's enrollment target sits among peer trials
8 29th of 29 higher than 1 of 29 other Multiple Sclerosis (Relapsing Remitting) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis (Relapsing Remitting) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
COMPLETED · Phase 3
-
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
COMPLETED · Phase 3
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI